International Stem Cell (OTCMKTS:ISCO – Get Free Report) posted its earnings results on Friday. The biotechnology company reported ($0.11) EPS for the quarter, Zacks reports.
International Stem Cell Stock Performance
Shares of ISCO opened at $0.17 on Friday. The stock has a market capitalization of $1.38 million, a PE ratio of -2.11 and a beta of 0.08. The company’s fifty day moving average is $0.24 and its 200 day moving average is $0.22. International Stem Cell has a fifty-two week low of $0.12 and a fifty-two week high of $0.54.
About International Stem Cell
International Stem Cell Corporation is a biotechnology company focused on developing products and therapies using its proprietary human parthenogenetic stem cell technology. These cells are created from unfertilized human eggs and have been studied for their potential use in regenerative medicine. The company has pursued stem cell-based programs for neurological conditions, including Parkinson’s disease, and has developed stem cell-derived ingredients for skin-care products sold through its Lifeline Skin Care business.
Featured Stories
- Five stocks we like better than International Stem Cell
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
Receive News & Ratings for International Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for International Stem Cell and related companies with MarketBeat.com's FREE daily email newsletter.
